Symbiotec Pharmalab Share Price: Stock Lists at Flat on NSE

On September 1, 2026, Symbiotec Pharmalab Ltd. shares made a flat debut on the stock exchanges, listing at ₹988.00 on the NSE, reflecting a no change to the upper end of the issue price band of ₹938–₹988 per share. 

While on BSE it listed at ₹978.20 at a discount of 0.99% to the upper end of the issue price band of ₹938–₹988 per share. 

Symbiotec Pharmalab IPO Overview 

Symbiotec Pharmalab Limited's ₹1,757.00 crore book-built IPO, comprising a ₹150.00 crore fresh issue and ₹1,607.00 crore offer for sale, was priced between ₹938 and ₹988 per share. With a minimum lot size of 15 shares, the offering was open during the subscription period of August 24–27, 2026, with allotment finalized on August 28, 2026. JM Financial Ltd. acted as the book-running lead manager, while MUFG Intime India Pvt. Ltd. served as the registrar for the issue. The IPO was subscribed 75.08 times. 

Business Overview of Symbiotec Pharmalab 

Symbiotec Pharmalab Limited is a research and development-focused specialty pharmaceutical company specializing in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs). Headquartered in Indore, Madhya Pradesh, India, the company has global volume market leadership in selected API segments, with manufacturing facilities in Rau and Pithampur that hold approvals from regulatory authorities including the US FDA, EU-GMP, and WHO-GMP. 

Financial Overview of Symbiotec Pharmalab 

Symbiotec Pharmalab Ltd. grew steadily up to March 2026. Revenue from operations reached ₹869.14 crore in FY26. Most notably, the company's profit after tax stood at ₹109.90 crore over the same period. The company operates with a strong margin profile, registering a net profit margin of approximately 12.60%. 

Symbiotec Pharmalab Share Price Performance 

As of September 01, 2026, at 10:23 AM, Symbiotec Pharmalab share price on NSE was trading at ₹975.45, down by 1.27% from the IPO issue price of ₹988.00. 

Read More: Zydus Lifesciences Share Price in Focus; Reports Positive Phase II(b) Trial Results for Saroglitazar Mg in MASH! 

Conclusion 

Symbiotec Pharmalab shares debuted flat on the NSE at ₹988.00, demonstrating a no change. The initial public offering raised a total of ₹1,757.00 crore. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.